莫林作为一种潜在的治疗化合物,针对结直肠癌细胞中的TP53和KRAS突变
Cheok Wui Chee1, Najihah Mohd Hashim2, Nurshamimi Nor Rashid3
1Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Chemico-biological interactions
|February 29, 2024
概括
莫林达叶 L. 炭素,达姆纳坎塔尔和莫林,通过抑制增殖和诱导亡,对结直肠癌 (CRC) 产生抗癌作用. 莫林是一种有前途的治疗CRC的药物.
科学领域:
- 药理学 药理学 是一个学科.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 结肠直肠癌 (CRC) 治疗面临的挑战是由于频繁的TP53和KRAS突变.
- 植物化学物质,特别是来自Morinda citrifolia L.的 antraquinones,正在被探索用于CRC的化学预防.
- 饮食因素是CRC的重要危险因素.
研究的目的:
- 为了研究damnacanthal和morindone对CRC细胞的体外抗癌作用.
- 评估这些 antraquinones 对细胞增殖,细胞循环和细胞亡的影响.
- 探索突变TP53和KRAS基因表达在CRC对 antraquinones反应中的作用.
主要方法:
- 在体外实验中使用HCT116和HT29结肠直肠癌细胞系.
- 实时细胞监测,细胞周期分析和光显微镜用于细胞亡评估.
- siRNA转染用于突变TP53和KRAS的基因淘汰,随后进行qRT-PCR和西部斑分析.
主要成果:
- 达姆纳坎塔尔和莫林都对CRC细胞表现出显著的剂量和时间依赖的抗增殖作用.
- 人类类治疗导致G1阶段细胞循环停止和亡的增加.
- 莫林降低了突变TP53和KRAS基因表达的调节,而这两种化合物都影响了蛋白质表达,使细胞对治疗敏感.
结论:
- 莫林表现出多种抗癌机制,可能是结直肠癌的竞争性治疗剂.
- 来自Morinda citrifolia L.的 antraquinones 显示出作为CRC的新型化学预防和治疗剂的潜力.
- 向突变TP53和KRAS通路可以提高这些天然化合物在CRC治疗中的疗效.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K